



Att. Docket No.: REG 711A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mark W. Sleeman et al.

Serial No.: 10/811,170

Group: 1635

Filing Date: March 26, 2004

Examiner: to be assigned

Title: Methods of Treating Diabetes by Blocking VEGF-Mediated Activity

**FIRST CLASS MAIL CERTIFICATE**

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, United States Patent and Trademark Office, P. O. Box 1450, Alexandria, VA 22313-1450.

Loren Hernandez  
Loren Hernandez

November 12, 2004

Date

Commissioner for Patents  
US Patent & Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56 and 1.97**

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and a copy of the reference listed therein. The PTO is kindly requested to make of record those references, which may be pertinent to the examination of the above-referenced application.


This Information Disclosure Statement is being filed:

After three months of the file date of the above referenced application, but before the mailing date of any of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under §1.114. Accordingly, no fee is required for the submission.

**Fees**


There is no fee required for the filing of this Information Disclosure Statement. In the event there is a fee inadvertently omitted, Applicants hereby authorizes the fee to be charge to Deposit Account number 18-0650.

Respectfully submitted



Valeta Gregg  
Reg. No. 35,127  
Attorney for Applicant  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400

FORM PTO-1449



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att Docket No. : REG 711A  
Serial No. : 10/811,170  
Applicant: : Mark W. Sleeman et al.  
Date Filed : March 26, 2004  
Examiner : to be assigned  
Group Art Unit : 1635

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes No</u>
_____	WO 00/75319A	14 Dec. 2000	PCT		
_____	WO 02/060489A	8 Aug. 2002	PCT		

OTHER DOCUMENTS

Examiner  
Initials

\_\_\_\_\_ US Patent Application Publication US 2003/0017977 A1, Xia et al.  
(Jan. 23, 2003).

EXAMINER  
CONSIDERED


DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:



Valeta Gregg  
Reg. No. 35,127  
Attorneys for Applicant  
Patent Agent for Applicant  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400